Piper Sandler lowered the firm’s price target on Vicarious Surgical (RBOT) to $8.50 from $10.50 and keeps a Neutral rating on the shares following quarterly results. Looking ahead to 2025, the company announced full year 2025 cash burn guidance of about $50M. The company also announced that it successfully completed the V1.0 system integration in Q4: 2024, which is an encouraging milestone in Piper’s view. However, the company did note some minor supply chain issues related to component suppliers that now positions first-in-human cases to take place in late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RBOT:
- Vicarious Surgical Reports 2024 Financial Results and Progress
- Vicarious Surgical’s Promising Progress: Buy Rating Affirmed Amid Strategic Milestones and Clinical Advancements
- Closing Bell Movers: Harrow spikes 24% on revenue beat, leverage update
- Vicarious Surgical reports Q4 adjusted EPS ($2.43), consensus ($2.69)
- Vicarious Surgical sees FY25 cash burn roughly $50M